Mr. Glenn P. Sblendorio, M.B.A., has been the President of Ophthotech Corporation since February 1, 2017 and has been its Chief Executive Officer since July 1, 2017. Mr. Sblendorio served as Chief Financial Officer and Treasurer of Ophthotech Corporation since April 1, 2016 until April 24, 2017. Mr. Sblendorio served as the Chief Operating Officer and Executive Vice President at Ophthotech Corporation from April 1, 2016 to February 1, 2017. Mr. Sblendorio served as the Strategic Advisor of The Medicines Company since January 1, 2016 until March 31, 2016. He served as President at The Medicines Company since February 21, 2012 and also its Chief Financial Officer since March 17, 2006 and its Treasurer. He served as Principal Accounting Officer of The Medicines Company and served as its Executive Vice President from March 17, 2006 to February 2012. He served as a Treasurer at Targanta Therapeutics Corp., a subsidiary of Medicines Co. since February 25, 2009. He joined The Medicines Company in March 2006. He served as an Executive Vice President and Chief Financial Officer of Oldtech, Inc. from 2002 to November 2005 and also served as its Principal Accounting Officer. Mr. Sblendorio served as Senior Vice President of Finance at Eyetech Pharmaceuticals since February 2002. He joined PlayNet Technologies Inc. in August 1996 and served as its Senior Vice President and Chief Financial Officer since August 1996. From July 2000 to February 2002, he served as Senior Vice President of Business Development for The Medicines Company and also served as its Principal Accounting Officer. From 1998 to July 2000, he served as the Chief Executive Officer, Chief Financial Officer and Managing Director of MPM Capital Advisors LLC. From July 1993 to August 1996, Mr. Sblendorio served as Chief Financial Officer of Sony Interactive Entertainment Inc. From October 1981 to July 1993, he served in various positions with the international drug and bio-technology conglomerate, F. Hoffmann La Roche. His pharmaceutical experience also includes 12 years at Hoffmann-La Roche Inc. in a variety of Senior Financial positions, including Chief Financial Officer of Roche Molecular Systems and Head of Finance-Controller for Amgen and Roche Europe. From March 1992 to July 1993, he served as Vice President of Finance of Roche Molecular Systems Inc. From January 1990 to March 1992, Mr. Sblendorio served as a Controller Europe for F. Hoffmann La Roche, Basel. From July 1989 to January 1990, he served as a Vice President of Finance and MIS for Medi Physics Inc. He serves as the Chairman of NuLens Ltd. He has been a Director of Ophthotech Corporation since May 19, 2017. He has been a Director at Intercept Pharmaceuticals, Inc. since February 18, 2014. He has been an Independent Director of Amicus Therapeutics, Inc. since June 2006. He served as a Director of Ophthotech Corporation since January 11, 2016 until March 2016 and previously served in the same position since July 2013 until January 5, 2016. He served as a Director at The Medicines Company since July 28, 2011 and Targanta Therapeutics Corp. since February 25, 2009. Mr. Sblendorio received B.B.A. in Accounting from Pace University and MBA in Finance from Fairleigh Dickinson University. Mr. Glenn P. Sblendorio, M.B.A., has been the President of Ophthotech Corporation since February 1, 2017 and has been its Chief Executive Officer since July 1, 2017. Mr. Sblendorio served as Chief Financial Officer and Treasurer of Ophthotech Corporation since April 1, 2016 until April 24, 2017. Mr. Sblendorio served as the Chief Operating Officer and Executive Vice President at Ophthotech Corporation from April 1, 2016 to February 1, 2017. Mr. Sblendorio served as the Strategic Advisor of The Medicines Company since January 1, 2016 until March 31, 2016. He served as President at The Medicines Company since February 21, 2012 and also its Chief Financial Officer since March 17, 2006 and its Treasurer. He served as Principal Accounting Officer of The Medicines Company and served as its Executive Vice President from March 17, 2006 to February 2012. He served as a Treasurer at Targanta Therapeutics Corp., a subsidiary of Medicines Co. since February 25, 2009. He joined The Medicines Company in March 2006. He served as an Executive Vice President and Chief Financial Officer of Oldtech, Inc. from 2002 to November 2005 and also served as its Principal Accounting Officer. Mr. Sblendorio served as Senior Vice President of Finance at Eyetech Pharmaceuticals since February 2002. He joined PlayNet Technologies Inc. in August 1996 and served as its Senior Vice President and Chief Financial Officer since August 1996. From July 2000 to February 2002, he served as Senior Vice President of Business Development for The Medicines Company and also served as its Principal Accounting Officer. From 1998 to July 2000, he served as the Chief Executive Officer, Chief Financial Officer and Managing Director of MPM Capital Advisors LLC. From July 1993 to August 1996, Mr. Sblendorio served as Chief Financial Officer of Sony Interactive Entertainment Inc. From October 1981 to July 1993, he served in various positions with the international drug and bio-technology conglomerate, F. Hoffmann La Roche. His pharmaceutical experience also includes 12 years at Hoffmann-La Roche Inc. in a variety of Senior Financial positions, including Chief Financial Officer of Roche Molecular Systems and Head of Finance-Controller for Amgen and Roche Europe. From March 1992 to July 1993, he served as Vice President of Finance of Roche Molecular Systems Inc. From January 1990 to March 1992, Mr. Sblendorio served as a Controller Europe for F. Hoffmann La Roche, Basel. From July 1989 to January 1990, he served as a Vice President of Finance and MIS for Medi Physics Inc. He serves as the Chairman of NuLens Ltd. He has been a Director of Ophthotech Corporation since May 19, 2017. He has been a Director at Intercept Pharmaceuticals, Inc. since February 18, 2014. He has been an Independent Director of Amicus Therapeutics, Inc. since June 2006. He served as a Director of Ophthotech Corporation since January 11, 2016 until March 2016 and previously served in the same position since July 2013 until January 5, 2016. He served as a Director at The Medicines Company since July 28, 2011 and Targanta Therapeutics Corp. since February 25, 2009. Mr. Sblendorio received B.B.A. in Accounting from Pace University and MBA in Finance from Fairleigh Dickinson University.

Eye Diseases and Disorders